Journal
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
Volume 130, Issue 3, Pages 563-571Publisher
MOSBY-ELSEVIER
DOI: 10.1016/j.jaci.2012.07.027
Keywords
Hypereosinophilic syndromes; eosinophil-associated gastrointestinal disorders; eosinophilic esophagitis; Churg-Strauss syndrome; IL-5; mepolizumab; reslizumab
Categories
Funding
- Division of Intramural Research, National Institute of Allergy and Infectious Diseases/National Institutes of Health (NIH)
- Office of Rare Diseases/NIH
- National Institutes of Health (NIH)
- GlaxoSmithKline
- Cephalon
- Novartis
- Sepracor/Sunovion
- Schering-Plough
- NKT Therapeutics
- Asthmatx/BSCI
- Genzyme
- MapPharma
- Genentech
- Boehringer Ingelheim
- National Institute of Allergy and Infectious Diseases
- National Heart, Lung, and Blood Institute
- UpToDate
- Elsevier
- Topigen Pharma
- TRIA Bioscience Corp
- ImmViz
- Teva
- Teva Pharmaceuticals
- NIH
- Pharmaxis
- Immune Pharmaceuticals
- UpToDate Online
- OPO Foundation Zurich
- Basilea Pharmaceutica
- Pfizer
Ask authors/readers for more resources
Hypereosinophilic syndromes (HESs) are a diverse group of conditions characterized by clinical manifestations attributable to eosinophilia and eosinophilic infiltration of tissues. HESs are chronic disorders with significant morbidity and mortality. Although the availability of targeted chemotherapeutic agents, including imatinib, has improved quality of life and survival in some patients with HESs, additional agents with increased efficacy and decreased toxicity are sorely needed. The purpose of this review is to provide an overview of eosinophil biology with an emphasis on potential targets of pharmacotherapy and to provide a summary of potential eosinophil-targeting agents, including those in development, in clinical trials, or approved for other disorders. (J Allergy Clin Immunol 2012;130:563-71.)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
